Haemonetics gets 510(k) for apheresis systems:
This article was originally published in Clinica
Executive Summary
Haemonetics has received US FDA clearance to market its MCS and MCS+ apheresis systems for use in therapeutic plasma exchange. Haemonetics stopped marketing the MCS system at the request of the FDA in March 1994, pending compilation of patient data.